<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02174900</url>
  </required_header>
  <id_info>
    <org_study_id>SAFEPRIM</org_study_id>
    <nct_id>NCT02174900</nct_id>
  </id_info>
  <brief_title>Safety of Primaquine + Artemether-lumefantrine in G6PD Deficient Males With an Asymptomatic Malaria Infection (SAFEPRIM)</brief_title>
  <official_title>Evaluation of the Safety of Primaquine in Combination With Artemether-lumefantrine in Glucose-6-phosphate Dehydrogynase Deficient Males With an Asymptomatic Malaria Infection in Burkina Faso (SAFEPRIM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre National de Recherche et de Formation sur le Paludisme, Burkina Faso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Nijmegen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerability and safety of increasing doses of
      primaquine in combination with artemether-lumefantrine in G6PD deficient males with an
      asymptomatic P. falciparum malaria infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Haemoglobin concentration relative to baseline value</measure>
    <time_frame>28 days</time_frame>
    <description>Haemoglobin concentration relative to baseline value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gametocyte clearance time</measure>
    <time_frame>14 days</time_frame>
    <description>Gametocyte clearance time</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>G6PD deficient 0.25 mg/kg PQ + AL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G6PD deficient males receiving Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G6PD deficient receiving AL only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>G6PD deficient males receiving Artemether-Lumefantrine (AL) combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G6PD normal 0.25 mg/kg PQ + AL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>G6PD normal males receiving Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G6PD normal 0.4 mg/kg PQ + AL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>G6PD normal males receiving Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G6PD-deficient 0.4 mg/kg PQ + AL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G6PD deficient males receiving Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine</intervention_name>
    <arm_group_label>G6PD deficient 0.25 mg/kg PQ + AL</arm_group_label>
    <arm_group_label>G6PD normal 0.25 mg/kg PQ + AL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-Lumefantrine (AL) combination</intervention_name>
    <arm_group_label>G6PD deficient receiving AL only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine</intervention_name>
    <arm_group_label>G6PD normal 0.4 mg/kg PQ + AL</arm_group_label>
    <arm_group_label>G6PD-deficient 0.4 mg/kg PQ + AL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male gender

          2. Age ≥18 years and ≤45 years

          3. BMI ≥16

          4. P. falciparum parasitaemia at any density

          5. G6PD deficiency by Beutler Fluorescent Spot test for intervention groups and control
             group receiving AL only (N=50)

          6. G6PD normal activity by Beutler Fluorescent Spot test for control groups (N=20)

          7. Informed consent by participant

        Exclusion Criteria:

          1. Enrolled in another clinical trial

          2. Fever &gt;37.5°C (tympanic) or history of fever in the last 24 hours

          3. Evidence of severe illness / danger signs or active infection other than malaria

          4. Known allergy to study medications

          5. Hb &lt;11 g/dL

          6. Antimalarials taken within the last 2 weeks

          7. PQ taken within the last 4 weeks and blood transfusion within the last 90 days

          8. Non-falciparum malaria co-infection

          9. Current use of tuberculosis or anti-retroviral medication, sulphonamides, dapsone,
             nitrofurantoin, , nalidixic acid, ciprofloxacin, , methylene blue, toluidine blue
             phenazopyridine and co-trimoxazole.

         10. History of severe chronic illness
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teun Bousema, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LSHTM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre National de Recherche et de Formation sur le Paludisme</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2014</study_first_posted>
  <last_update_submitted>January 29, 2016</last_update_submitted>
  <last_update_submitted_qc>January 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>G6PD deficiency</keyword>
  <keyword>safety</keyword>
  <keyword>transmission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Primaquine</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

